Clinical Trial Update: Aumolertinib Combined Intrathecal Chemotherapy for Leptomeningeal Metastasis From EGFR-Mutated NSCLC and Prognostic Value of Dynamic Changes in cfDNA Profiles [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluates aumolertinib combined with intrathecal chemotherapy for leptomeningeal metastasis in EGFR-mutated non-small cell lung cancer …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Aumolertinib (Aumolertinib)

Snippet

Sponsor: Three Gorges Hospital of Chongqing University | Conditions: Non-small Cell Lung Cancer | Phase 2 | Status: UNKNOWN